Pacific Biosciences (PACB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Sales | 160,005 | 154,014 | 200,521 | 128,304 | 130,513 |
| Cost of Goods | 114,225 | 116,732 | 147,741 | 79,269 | 71,653 |
| Gross Profit | 45,780 | 37,282 | 52,780 | 49,035 | 58,860 |
| Operating Expenses | 599,866 | 512,327 | 387,988 | 356,500 | 269,948 |
| Operating Income | -553,861 | -474,313 | -334,467 | -307,196 | -210,435 |
| Interest Expense | 6,954 | 13,412 | 14,343 | 14,690 | 12,530 |
| Other Income | 14,757 | 178,190 | 30,651 | 7,638 | -51,907 |
| Pre-tax Income | -546,058 | -309,535 | -318,159 | -314,248 | -274,872 |
| Income Tax | 318 | 316 | -11,424 | N/A | -93,649 |
| Net Income Continuous | -546,376 | -309,851 | -306,735 | -314,248 | -181,223 |
| Net Income | $-546,376 | $-309,851 | $-306,735 | $-314,248 | $-181,223 |
| EPS Basic Total Ops | -1.82 | -1.13 | -1.21 | -1.40 | -0.89 |
| EPS Basic Continuous Ops | -1.82 | -1.13 | -1.21 | -1.40 | -0.89 |
| EPS Diluted Total Ops | -1.82 | -1.59 | -1.21 | -1.40 | -0.89 |
| EPS Diluted Continuous Ops | -1.82 | -1.07 | -1.21 | -1.40 | -0.89 |
| EPS Diluted Before Non-Recurring Items | -0.53 | -0.83 | -1.11 | -1.38 | -0.93 |
| EBITDA(a) | $-156,814 | $-249,506 | $-320,773 | $-290,122 | $-194,839 |